miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

[1]  Ignacio I Wistuba,et al.  Lung Cancer Biomarkers. , 2017, Hematology/oncology clinics of North America.

[2]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[3]  Lihua Huang,et al.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.

[4]  B. Liu,et al.  MicroRNA-19 triggers epithelial–mesenchymal transition of lung cancer cells accompanied by growth inhibition , 2015, Laboratory Investigation.

[5]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[6]  Yanqiong Zhang,et al.  A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma , 2015, RNA biology.

[7]  G. Thomas,et al.  miR-19–Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer , 2015, Molecular Cancer Research.

[8]  Xu-guang Wang,et al.  MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation. , 2015, International journal of molecular medicine.

[9]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[10]  Shree Ram Singh,et al.  The emerging roles of microRNAs in cancer metabolism. , 2015, Cancer letters.

[11]  Wenting Liu,et al.  The role of exosomes and "exosomal shuttle microRNA" in tumorigenesis and drug resistance. , 2015, Cancer letters.

[12]  M. Barbareschi,et al.  MicroRNAs as lung cancer biomarkers. , 2014, World journal of clinical oncology.

[13]  R. Wu,et al.  Curcumin Modulates miR‐19/PTEN/AKT/p53 Axis to Suppress Bisphenol A‐induced MCF‐7 Breast Cancer Cell Proliferation , 2014, Phytotherapy research : PTR.

[14]  Hongchuan Jin,et al.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. , 2014, American journal of cancer research.

[15]  Ping Yang,et al.  miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer , 2014, Journal of Experimental & Clinical Cancer Research.

[16]  A. Roccaro,et al.  Regulation of microRNAs in cancer metastasis. , 2014, Biochimica et biophysica acta.

[17]  Q. Wu,et al.  MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1 , 2014, Cell Death and Disease.

[18]  L. Trusolino,et al.  Targeting the MET gene for the treatment of non-small-cell lung cancer. , 2014, Critical reviews in oncology/hematology.

[19]  Jae Cheol Lee,et al.  MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.

[20]  Juan Lin,et al.  Serum miR‐19a expression correlates with worse prognosis of patients with non‐small cell lung cancer , 2013, Journal of surgical oncology.

[21]  P. Jänne,et al.  Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. , 2013, Cancer research.

[22]  J. Gong,et al.  Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells , 2012, Cell Death and Differentiation.

[23]  J. Blenis,et al.  Down-regulation of CMTM8 Induces Epithelial-to-Mesenchymal Transition-like Changes via c-MET/Extracellular Signal-regulated Kinase (ERK) Signaling* , 2012, The Journal of Biological Chemistry.

[24]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[25]  C. Croce,et al.  EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[26]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[27]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[28]  William Ritchie,et al.  Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia , 2010, Haematologica.

[29]  S. Lowe,et al.  miR-19 is a key oncogenic component of mir-17-92. , 2009, Genes & development.

[30]  Yunjung Choi,et al.  Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. , 2009, Lung cancer.

[31]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[32]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[33]  Masahiro Fukuoka,et al.  Gefitinib — a novel targeted approach to treating cancer , 2004, Nature Reviews Cancer.

[34]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[35]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[36]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.